APCCC 2019 PRESENTATION SLIDES

Get Free Access to Session Slides

APCCC 2019 VL

Interpreting Phase III Clinical Trial Data - Susan Halabi

Details
During the 2019 Advanced Prostate Cancer Consensus Conference (APCCC 2019), Susan Halabi joined Alicia Morgans to help interpret the various ongoing stage III clinical trials in prostate cancer. Dr. Halabi shares the top errors we can avoid in subgroup analyses. Biographies: Susan Halabi, Ph.D., Professor of Biostatistics and Bioinformatics, Duke Cancer Institute, Durham, North Carolina, United St...

Assessing the Aging Population and Treatment Considerations for Prostate Cancer - Joe O'Sullivan

Details
At the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Joe O'Sullivan joins Phillip Koo to discuss the onco-geriatric population, why it is referred to as a ticking time bomb, and the unique challenges it presents to the community. Biographies: Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Professor of Radiation Oncology, Queen's University Belfast, Consultant Oncologist, Northern Irela...

Systemic Therapies for Node-Positive Non-Metastatic Castration Resistant Prostate Cancer - Nicholas James

Details
Nicholas James joins Alicia Morgans at the Advanced Prostate Cancer Consensus Conference (APCCC) to discuss systemic therapies for node-positive patients. Professor James discusses the three main questions to his presentation: What's the role of radiotherapy? What systemic therapies do you give with radiotherapy? Do you give ADT plus something else? Biographies: Professor Nicholas James BSc, MB, B...

Which Men Need Genetic Counseling and/or Testing? Presentation - Ros Eeles

Details
During the Molecular Biomarkers and Novel Imaging in Advanced Prostate Cancer session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Dr. Rosalind Eeles discussed how patients should be selected for genetic counseling and testing. She highlights several key points for clinicians to consider when thinking through how we should think about which men should be tested for genetic ab...

Immunotherapy in Metastatic Prostate Cancer - Charles Drake

Details
Charles Drake, a leader in the research of immunology in castration-resistant prostate cancer, (mCRPC) discusses the evolution of immunotherapy in prostate cancer. Together with Charles Ryan, in this discussion, he focuses on the best combination therapies and MSI-high disease in metastatic prostate cancer. Biographies: Charles G. Drake, MD, Ph.D., Department of Medicine, Division of Hematology/On...

Managing the Complications of Androgen Deprivation Therapy - Mark Frydenberg

Details
A more common but often less talked about negative side effect of androgen deprivation therapy is the presence of hot flushes in men. In this discussion with Carmel Pezaro, Mark Frydenberg highlights solutions to this issue ranging from simple everyday adaptations to investigating alternative complementary therapies and drugs. Biographies: Mark Frydenberg, MD, Vice President, President-elect, Urol...

Pharmaco-ethnicity and its Impact on Prostate Cancer Treatment - Darren MC Poon

Details
Darren Poon joins Alicia Morgans to discuss his presentation on pharmaco-ethnicities specifically as it relates to drug toxicities in Asian patients, and why it is important to think about on a wider scale at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Dr. Poon addresses the importance that ethnic backgrounds have on the treatment of prostate cancer, largely arguing that these...

Treating the Primary in High vs Low Volume Hormone Sensitive Disease - Interview Noel Clarke

Details
Using various volume and risk criteria used worldwide for the treatment related to docetaxel and abiraterone in metastatic hormone-sensitive prostate cancer, Noel Clarke and colleagues have gathered and correlated large volumes of imaging data on treatment and outcomes from within the UK within the STAMPEDE trial. In his discussion with Charles Ryan, Noel Clarke shares details of the sub-analysis...

Imaging Modalities to Treat Node-Positive Disease - Interview with Declan Murphy

Details
Declan Murphy sits down with Alicia Morgans during the Advanced Prostate Cancer Consensus Conference (APCCC 2019) to discuss men who have node positive but nonmetastatic prostate cancer and how we think about approaching treatment and integrating new imaging modalities into that entire therapeutic paradigm. Two aspects of managing node positive men in regards to surgery were talked about including...

Optimal Treatment of Newly Diagnosed Metastatic Prostate Cancer Presentation - Noel Clarke

Details
Noel Clarke presented on the optimization of the treatment of newly diagnosed metastatic prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Among the topics he covers in this presentation include the STAMPEDE biomedical imaging group (BIG) and STAMPEDE biomedical research group (BRG) which have incorporated 5,000 CT and bone scans with a target of more than 10,000,...